Gilead Didn't Pay Teva In HIV Drug IP Deal, Economist Says
An economics expert for Gilead and Teva, testifying Monday in a federal antitrust trial over claims the pharmaceutical giants struck an illegal "pay for delay" patent deal over two HIV medications,...To view the full article, register now.
Already a subscriber? Click here to view full article